Indication name: Chordoma
"Chordoma –
Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report
– 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom,
Italy, Japan & China)
A chordoma is a
rare type of cancerous tumor that can occur anywhere along the spine, from the
base of the skull to the tailbone. Chordomas grow slowly, gradually extending
into the bone and soft tissue around them. Changes in the TBXT gene have been
associated with chordoma. The TBXT gene provides instructions for making a
protein called brachyury.
According to
Thelansis, worldwide one in one million people are diagnosed with chordoma per
year.
Competitive
landscape of Chordoma includes country specific approved as well as pipeline
therapies. Any asset/ product specific designation or review and Accelerated
Approval are being tracked and supplemented with analyst commentary.
KOLs insights of
Chordoma across 8 MM market from center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm
and Unmet needs.
Chordoma Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)
which Data Inputs with sourcing, Market Event and Product Event, Country
specific Forecast Model, Market uptake and patient share uptake, Attribute
Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and
Insights.
S. No Asset Company Stage
1 TAEK-VAC-HerBy Bavarian Nordic Phase 2
2 GI-6301 NantCell, Inc. Phase 2
3 FAZ053 Novartis Pharmaceuticals Phase
1
4 Nivolumab Bristol-Myers Squibb Phase
2
5 Pemetrexed Eli Lilly and Company Phase
1
6 Afatinib Boehringer Ingelheim Phase 2
7 BCA101 Bicara Therapeutics Phase
1"
No comments:
Post a Comment